A Retrospective Pooled Analysis of Complete Remission Among Pediatric Patients With Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Amgen1 site in 1 country207 target enrollmentDecember 9, 2014

ConditionsB-cell Precursor Acute Lymphoblastic Leukemia (ALL)

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Sponsor: Amgen
Enrollment: 207
Locations: 1
Primary Endpoint: Hematological Complete Remission (CR)
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

An historical data comparator study for children with relapsed/refactory acute lymphoblastic leukemia (ALL).

Detailed Description

A retrospective observational study reviewing historical complete remission for pediatric patients who had either relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL)

Registry

clinicaltrials.gov

Start Date

December 9, 2014

End Date

January 22, 2015

Last Updated

5 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Amgen

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Hematological Complete Remission (CR)

Time Frame: Approx. 1 year

To estimate hematological Complete Remission (CR) in pediatric patients with relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL)